Regeneron Pharma’s adjusted earnings beat estimates

  • 📰 MarketWatch
  • ⏱ Reading Time:
  • 16 sec. here
  • 2 min. at publisher
  • 📊 Quality Score:
  • News: 10%
  • Publisher: 97%

Malaysia News News

Malaysia Malaysia Latest News,Malaysia Malaysia Headlines

Steve Gelsi covers banking and cannabis as a Senior Reporter for MarketWatch.

Regeneron Pharmaceuticals Inc.’s stock REGN, +1.46% rose fractionally on Thursday after the drug maker said its profit dropped by 23%, while its adjusted results beat analyst expectations. Regeneron said its third-quarter net income fell 23% to $1 billion, or $8.89 a share, from $1.

32 billion, or $11.66 a share, in the year-ago quarter. Third-quarter adjusted profit rose to $11.59 a share from $11.14 a share in the year-ago period and beat the FactSet consensus estimate of $10.68 a share. Revenue climbed 15% to $3.36 billion, ahead of the Wall Street analyst expectation of $3.23 billion.

 

Thank you for your comment. Your comment will be published after being reviewed.
Please try again later.
We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more:

 /  🏆 3. in MY

Malaysia Malaysia Latest News, Malaysia Malaysia Headlines

Similar News:You can also read news stories similar to this one that we have collected from other news sources.

Ares Acquisition Corp., X-energy scrap $1.8B merger due to ‘persistently volatile public markets’Steve Gelsi covers banking and cannabis as a Senior Reporter for MarketWatch.
Source: MarketWatch - 🏆 3. / 97 Read more »